NeoGenomics Launches PanTracer Pro for Solid Tumor Therapy Selection

New comprehensive genomic profiling solution aims to help clinicians make informed decisions faster for advanced-stage cancer patients.

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

NeoGenomics, a leading provider of oncology diagnostic solutions, has announced the availability of PanTracer Pro, a new addition to its PanTracer® Family. PanTracer Pro is designed to help clinicians navigate complex molecular testing workflows and support informed decisions for patients with advanced-stage solid tumors. The solution integrates broad genomic profiling with diagnosis-directed immunohistochemistry and ancillary testing to deliver comprehensive, guideline-aligned insights through a single coordinated order.

Why it matters

As precision oncology continues to evolve, clinicians face growing diagnostic complexity, increasing biomarker requirements, and mounting pressure to initiate treatment quickly. PanTracer Pro aims to address these challenges by enabling earlier access to relevant biomarker insights, reducing diagnostic uncertainty, and supporting confident clinical decisions earlier in the care journey.

The details

PanTracer Pro combines broad, comprehensive genomic profiling (CGP) with diagnosis-directed immunohistochemistry (IHC) and ancillary testing. By delivering these insights through a single coordinated order, the solution helps ensure relevant biomarkers are assessed upfront rather than through multiple, sequential tests. PanTracer Pro also has the ability to automatically reflex to NeoGenomics' pan-solid tumor liquid biopsy assay, PanTracer LBx™, when tissue samples are insufficient or unavailable.

  • PanTracer Pro is now available from NeoGenomics.

The players

NeoGenomics, Inc.

A leading provider of oncology diagnostic solutions that enable precision medicine.

Tony Zook

Chief executive officer at NeoGenomics.

Got photos? Submit your photos here. ›

What they’re saying

“Every delay or unanswered question in the diagnostic process can affect how quickly patients begin treatment. PanTracer Pro is designed to help clinicians get the information they need earlier and more reliably, so care teams can plan next steps with greater clarity and confidence across the care journey.”

— Tony Zook, Chief executive officer (BusinessWire)

The takeaway

PanTracer Pro aims to streamline complex molecular testing workflows and provide clinicians with comprehensive, guideline-aligned insights earlier in the diagnostic process. This can help support timely, informed treatment decisions for patients with advanced-stage solid tumors, potentially improving outcomes in an increasingly complex precision oncology landscape.